Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 218


Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule.

Darkoh C, Plants-Paris K, Bishoff D, DuPont HL.

mSystems. 2019 Mar 19;4(2). pii: e00346-18. doi: 10.1128/mSystems.00346-18. eCollection 2019 Mar-Apr.


Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.

Steffen R, DuPont HL.

J Travel Med. 2019 May 10;26(3). pii: taz014. doi: 10.1093/jtm/taz014. No abstract available.


Occurrence of putative virulence-related genes, aatA, aggR and aaiC, of Enteroaggregative Escherichia coli (EAEC) among adults with travelers' diarrhea acquired in Guatemala and Mexico.

Bamidele O, Jiang ZD, Dupont H.

Microb Pathog. 2019 Mar;128:97-99. doi: 10.1016/j.micpath.2018.12.030. Epub 2018 Dec 21.


Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a prospective cohort study protocol.

Lindsay L, DuPont HL, Moe CL, Alberer M, Hatz C, Kirby AE, Wu HM, Verstraeten T, Steffen R.

BMC Infect Dis. 2018 Dec 3;18(1):605. doi: 10.1186/s12879-018-3461-6.


Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.

Steffen R, Jiang ZD, Gracias Garcia ML, Araujo P, Stiess M, Nacak T, Greinwald R, DuPont HL.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay116.


Visualization-assisted binning of metagenome assemblies reveals potential new pathogenic profiles in idiopathic travelers' diarrhea.

Zhu Q, Dupont CL, Jones MB, Pham KM, Jiang ZD, DuPont HL, Highlander SK.

Microbiome. 2018 Nov 8;6(1):201. doi: 10.1186/s40168-018-0579-0.


Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.

Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL.

PLoS One. 2018 Nov 2;13(11):e0205064. doi: 10.1371/journal.pone.0205064. eCollection 2018.


Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.

Dogan B, Belcher-Timme HF, Dogan EI, Jiang ZD, DuPont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW.

FEMS Microbiol Lett. 2018 Nov 1;365(22). doi: 10.1093/femsle/fny249.


Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: Systematic review.

Valilis E, Ramsey A, Sidiq S, DuPont HL.

Int J Infect Dis. 2018 Nov;76:82-87. doi: 10.1016/j.ijid.2018.09.002. Epub 2018 Sep 14.


Search for the optimal antimicrobial therapy of Clostridium difficile infection.

DuPont HL.

Lancet Infect Dis. 2018 Sep;18(9):936-937. doi: 10.1016/S1473-3099(18)30308-6. Epub 2018 Jul 17. No abstract available.


High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya.

Oyaro MO, Plants-Paris K, Bishoff D, Malonza P, Gontier CS, DuPont HL, Darkoh C.

Int J Infect Dis. 2018 Sep;74:24-28. doi: 10.1016/j.ijid.2018.06.014. Epub 2018 Jun 28.


New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases.

Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J.

Dig Liver Dis. 2018 Aug;50(8):741-749. doi: 10.1016/j.dld.2018.04.020. Epub 2018 Apr 27. Review.


Gastric Acid and Enteric Infections: Souring on the Use of PPIs.

DuPont HL.

Dig Dis Sci. 2018 Apr;63(4):814-817. doi: 10.1007/s10620-018-4955-1. No abstract available.


Erratum for Darkoh et al., "Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile".

Darkoh C, Odo C, DuPont HL.

MBio. 2017 Oct 31;8(5). pii: e01643-17. doi: 10.1128/mBio.01643-17. No abstract available.


Comment: Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin.

DuPont HL, Bajaj JS.

Ann Pharmacother. 2018 Jan;52(1):94-95. doi: 10.1177/1060028017738263. Epub 2017 Oct 25. No abstract available.


Clinical features and molecular epidemiology of diarrheagenic Escherichia coli pathotypes identified by fecal gastrointestinal multiplex nucleic acid amplification in patients with cancer and diarrhea.

Chao AW, Bhatti M, DuPont HL, Nataro JP, Carlin LG, Okhuysen PC.

Diagn Microbiol Infect Dis. 2017 Nov;89(3):235-240. doi: 10.1016/j.diagmicrobio.2017.08.004. Epub 2017 Aug 12.


Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI).

Jiang ZD, Alexander A, Ke S, Valilis EM, Hu S, Li B, DuPont HL.

Anaerobe. 2017 Dec;48:110-114. doi: 10.1016/j.anaerobe.2017.08.003. Epub 2017 Aug 9.


Nonantimicrobial drug targets for Clostridium difficile infections.

Darkoh C, Deaton M, DuPont HL.

Future Microbiol. 2017 Sep;12:975-985. doi: 10.2217/fmb-2017-0024. Epub 2017 Jul 31.


Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Riddle MS, Connor BA, Beeching NJ, DuPont HL, Hamer DH, Kozarsky P, Libman M, Steffen R, Taylor D, Tribble DR, Vila J, Zanger P, Ericsson CD.

J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. doi: 10.1093/jtm/tax026. Review.

Supplemental Content

Loading ...
Support Center